Dermapharm Holding SE Working Capital to Net Assets Ratio
Dermapharm Holding SE working capital to net assets ratio. Dermapharm Holding SE (DMP) has a Working Capital to Net Assets ratio of 53.0% as of March 2026. Working capital of €389.81 Million (current assets of €780.05 Million minus current liabilities of €390.24 Million) is measured against net assets of €735.17 Million. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Dermapharm Holding SE (2013–2025)
Working capital to net assets ratio of Dermapharm Holding SE from 2013 to 2025. This chart shows how Dermapharm Holding SE's Working Capital to Net Assets ratio has evolved across 13 annual periods from 2013 to 2025. As of March 2026, the ratio stands at 53.0%, reflecting working capital of €389.81 Million against net assets of €735.17 Million EUR. Explore Dermapharm Holding SE (DMP) investment intensity to see how much of total assets are deployed in long-term investments.
Dermapharm Holding SE Working Capital to Net Assets Ratio by Year (2013–2025)
Dermapharm Holding SE working capital to net assets ratio by year from 2013 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Dermapharm Holding SE from 2013 to 2025, covering 13 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see DMP total asset value.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 51.3% | €360.00 Million | €701.83 Million | €702.92 Million | €342.93 Million | ▲ +7.5 pp |
| 2024 | 43.8% | €266.58 Million | €608.29 Million | €593.50 Million | €326.92 Million | ▲ +0.5 pp |
| 2023 | 43.3% | €236.01 Million | €545.05 Million | €630.50 Million | €394.49 Million | ▼ -16.1 pp |
| 2022 | 59.4% | €316.15 Million | €532.49 Million | €533.95 Million | €217.79 Million | ▼ -13.4 pp |
| 2021 | 72.7% | €363.61 Million | €499.83 Million | €519.22 Million | €155.61 Million | ▼ -9.6 pp |
| 2020 | 82.3% | €267.18 Million | €324.58 Million | €400.05 Million | €132.87 Million | ▼ -5.7 pp |
| 2019 | 88.1% | €250.52 Million | €284.49 Million | €352.94 Million | €102.42 Million | ▲ +0.3 pp |
| 2018 | 87.8% | €224.84 Million | €256.08 Million | €371.24 Million | €146.40 Million | ▼ -64.6 pp |
| 2017 | 152.4% | €112.29 Million | €73.69 Million | €192.87 Million | €80.58 Million | ▲ +84.1 pp |
| 2016 | 68.3% | €41.54 Million | €60.81 Million | €156.96 Million | €115.42 Million | ▼ -112.9 pp |
| 2015 | 181.2% | €80.53 Million | €44.44 Million | €142.10 Million | €61.57 Million | ▼ -29.0 pp |
| 2014 | 210.2% | €71.50 Million | €34.01 Million | €168.54 Million | €97.04 Million | ▲ +178.2 pp |
| 2013 | 32.0% | €13.24 Million | €41.36 Million | €181.90 Million | €168.66 Million | — |